S Percy Ivy

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint NCI cooperative research and development agreements
    S P Ivy
    Developmental Chemotherapy Section, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA
    Oncology (Williston Park) 14:27-9. 2000
  2. doi request reprint Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee
    S Percy Ivy
    Investigational Drug Branch and Biometrics Research Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 16:1726-36. 2010
  3. doi request reprint An overview of small-molecule inhibitors of VEGFR signaling
    S Percy Ivy
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    Nat Rev Clin Oncol 6:569-79. 2009
  4. pmc First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 19:1852-7. 2013
  5. doi request reprint Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
    Naoko Takebe
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, EPN7131, 6130 Executive Boulevard, Rockville, Bethesda, MD 20852, USA
    Nat Rev Clin Oncol 8:97-106. 2011
  6. pmc Cediranib for metastatic alveolar soft part sarcoma
    Shivaani Kummar
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 31:2296-302. 2013
  7. pmc Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition
    Naoko Takebe
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Rockville, Maryland 20852, USA
    Breast Cancer Res 13:211. 2011
  8. ncbi request reprint Design issues of randomized phase II trials and a proposal for phase II screening trials
    Lawrence V Rubinstein
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 23:7199-206. 2005
  9. doi request reprint Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011
    Jason J Luke
    Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Melanoma Res 23:152-8. 2013
  10. ncbi request reprint Heat shock protein 90
    Len Neckers
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, USA
    Curr Opin Oncol 15:419-24. 2003

Collaborators

Detail Information

Publications13

  1. ncbi request reprint NCI cooperative research and development agreements
    S P Ivy
    Developmental Chemotherapy Section, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA
    Oncology (Williston Park) 14:27-9. 2000
    ..The CTEP/Investigational Drug Branch is currently involved in a number of oxaliplatin (Eloxatin) protocols under the CRADA program...
  2. doi request reprint Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee
    S Percy Ivy
    Investigational Drug Branch and Biometrics Research Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 16:1726-36. 2010
    ..The approaches outlined in this overview address the merits, advantages, disadvantages, and obstacles encountered during first in human studies...
  3. doi request reprint An overview of small-molecule inhibitors of VEGFR signaling
    S Percy Ivy
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    Nat Rev Clin Oncol 6:569-79. 2009
    ..The on-target effects seem to be mechanistically based and predicted by VEGFR inhibition. Small-molecule inhibitors of angiogenesis are active in a wide variety of malignancies and fill a unique niche for cancer therapeutics...
  4. pmc First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies
    Shivaani Kummar
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 19:1852-7. 2013
    ..i.v. infusion before embarking on large-scale clinical trials. Plasma concentrations of IPdR, IdUrd, and other metabolites were measured after a single oral dose of IPdR...
  5. doi request reprint Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
    Naoko Takebe
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, EPN7131, 6130 Executive Boulevard, Rockville, Bethesda, MD 20852, USA
    Nat Rev Clin Oncol 8:97-106. 2011
    ..The role that embryonic signaling pathways play in the function of CSCs, the development of new anti-CSC therapeutic agents, and the complexity of potential CSC signaling cross-talk are described in this Review...
  6. pmc Cediranib for metastatic alveolar soft part sarcoma
    Shivaani Kummar
    National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Clin Oncol 31:2296-302. 2013
    ..Cediranib is a potent, oral small-molecule inhibitor of all three vascular endothelial growth factor receptors (VEGFRs)...
  7. pmc Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition
    Naoko Takebe
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Rockville, Maryland 20852, USA
    Breast Cancer Res 13:211. 2011
    ..In this review, we examine embryonic signaling pathways, CSCs, and factors affecting EMT...
  8. ncbi request reprint Design issues of randomized phase II trials and a proposal for phase II screening trials
    Lawrence V Rubinstein
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 23:7199-206. 2005
    ....
  9. doi request reprint Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011
    Jason J Luke
    Melanoma Disease Center, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Melanoma Res 23:152-8. 2013
    ..However, this difference in toxicity may have been largely because of the nature of phase I vs. phase III trials (i.e. more heavily pretreated) and because of the phase I trials often being multiagent as opposed to dacarbazine alone...
  10. ncbi request reprint Heat shock protein 90
    Len Neckers
    Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, USA
    Curr Opin Oncol 15:419-24. 2003
    ..Hsp90 inhibitors are unique in that, although they are directed towards a specific molecular target, they simultaneously inhibit multiple signaling pathways that frequently interact to promote cancer cell survival...
  11. ncbi request reprint Controversies in cancer stem cells: targeting embryonic signaling pathways
    Naoko Takebe
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, Bethesda, MD 20852, USA
    Clin Cancer Res 16:3106-12. 2010
    ..We also examine the scope and stage of development of early experimental agents that specifically target these highly conserved embryonic signaling pathways...
  12. pmc Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies
    Shivaani Kummar
    Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Eur J Cancer 46:340-7. 2010
    ....
  13. ncbi request reprint Proceedings of the Oxygen Homeostasis/Hypoxia Meeting
    Bennett Kaufman
    TRI Inc, Rockville, Maryland, USA
    Cancer Res 64:3350-6. 2004